Search the GHTC website

Global health R&D delivers for Colorado

US government investment in global health R&D has delivered

$332.9 million
to Colorado research institutions
5,000+ new jobs
for Colorado
Colorado's top USG-funded global health R&D institutions

Colorado's top USG-funded global health R&D institutions

Colorado State University
$152.8 million
University of Colorado, Denver
$119.7 million
LightDeck Diagnostics (formerly MBio Diagnostics)
$14 million
National Jewish Health
$11.8 million
University of Colorado, Boulder
$7.2 million
Inviragen Inc.*
$5.9 million
Palantir Technologies
$5 million
GlobeImmune Inc.
$4.9 million
Aerosol Devices Inc.
$1.9 million
University of Denver
$1.9 million
Corgenix Medical Corporation
$1.8 million
Precision Photonics Corporation*
$1.7 million
Colorado School of Mines
$1.3 million
Pharmajet, Inc.
$738 thousand
Zayo Group Holdings Inc.
$530 thousand
Denver Research Institute
$421 thousand
Bolder Biotechnology Inc.
$292 thousand
Aerophase Inc.*
$278 thousand
Taiga Biotechnologies Inc.
$230 thousand
ADA Technologies Inc.
$191 thousand
Keystone Symposia on Molecular and Cellular Biology
$167 thousand
GT Molecular
$128 thousand

Colorado's top areas of global health R&D by USG funding

Diarrheal diseases
Neglected tropical diseases
Helminth infections (Worms & Flukes)
Kinetoplastid diseases
Salmonella infections
Bacterial pneumonia & meningitis
Bunyaviral diseases (including CCHF, RVF, SFTS)
Emergent non-polio enteroviruses (including EV71, D68)
Filoviral diseases (including Ebola, Marburg)
Multi-disease/health area R&D
Other coronaviruses (including MERS, SARS)
Reproductive health
Global health R&D at work in Colorado

University of Colorado School of Medicine researchers discovered that a process that protects the body from autoimmune disease also blocks the production of antibodies against HIV-1, the most common cause of AIDS. The immune system normally suppresses these antibodies to keep them from targeting healthy tissues; the question now is whether there are ways to temporarily halt this mechanism, allowing one’s body to generate antibodies capable of neutralizing HIV-1 without harm to patients. The findings could help scientists develop a vaccine.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: PATH/Patrick McKern